MINI FUTURE LONG - NOVO-NORDISK B | Real-time Euronext Paris 14:19:45 03/06/2024 BST | ||
| 12.82 EUR | -1.65% |
|
| 1 month | +6.67% | ||
| 3 months | +25.89% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 03/06/24 | 12.82 | -1.65% |
| 31/05/24 | 13.03 | +1.05% |
| 30/05/24 | 12.9 | +1.02% |
| 29/05/24 | 12.76 | -0.93% |
| 28/05/24 | 12.88 | -0.73% |
Real-time Euronext Paris
Last update June 03, 2024 at 02:19 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
BNP Paribas
|
| UF5KB | |
| ISIN | FRBNPP05KAB7 |
| Date issued | 31/03/2023 |
| Strike | 442.5 kr |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 3.46 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 13.49 € |
|---|---|
| Lowest since issue | 2.305 € |
| Spread | 0.01 € |
| Spread % | 0.08% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
927.3
DKK
Average target price
917.2
DKK
Spread / Average Target
-1.09%
- Stock Market
- Certificates
- UF5KB Certificat
